AstraZeneca Pharma gets CSDCO nod to import anti-cancer drug Lynparza

2 hours ago 1

AstraZeneca Pharma India Ltd connected Tuesday said it has received support from the Indian cause regulator for the import for merchantability and organisation of crab attraction cause Lynparza.

In a regulatory filing, the institution said it has received support from the Central Drugs Standard Control Organisation (CSDCO), Directorate General of Health Services, Government of India, to import for merchantability and organisation of Olaparib film-coated Tablets 100 mg and 150 mg (Lynparza).

Olaparib successful operation with Durvalumab is indicated for the attraction attraction of big patients with precocious oregon recurrent endometrial crab whose illness has not progressed connected first-line attraction with Durvalumab successful operation with platinum-based chemotherapy, it said.

"The receipt of this support paves mode for the motorboat of Olaparib film-coated tablets 100 mg and 150 mg (Lynparza) successful India for the supra specified further indication, taxable to the receipt of related statutory approvals...," the institution added.

*** Disclaimer: This Article is auto-aggregated by a Rss Api Program and has not been created or edited by Nandigram Times

(Note: This is an unedited and auto-generated story from Syndicated News Rss Api. News.nandigramtimes.com Staff may not have modified or edited the content body.

Please visit the Source Website that deserves the credit and responsibility for creating this content.)

Watch Live | Source Article